Sotalol is an active substance from the group of non-selective beta-blockers used for the treatment of cardiac arrhythmias. It has sympatholytic properties and prolongs the action potential. The tablets are administered two to three times daily before meals. Sotalol has a high interaction potential. The most common possible adverse effects include bradycardia, respiratory disturbances, fatigue, dizziness, and weakness. Sotalol has a high potential for drug interactions. As with other antiarrhythmic agents, sotalol itself may also promote the development of cardiac arrhythmias.
Sotalol (ATC C07AA07) has antiarrhythmic and sympatholytic properties. It is a non-selective, hydrophilic beta-blocker and additionally a Class III antiarrhythmic agent. Its effects are based on antagonism at beta-adrenoceptors and prolongation of the terminal phase of the action potential / repolarisation. The half-life is approximately 12 hours.
⚠️ Warnings
• Caution should be exercised in patients with history of heart or liver diseases, asthma or breathing difficulties, any allergy, diabetes, overactive thyroid, poor blood circulation, myasthenia gravis (muscle weakening disease), chest pain, phaeochromocytoma (growth of the adrenal gland), elderly, children, during pregnancy and breastfeeding.
• It may cause dizziness, drowsiness or lightheadedness, do not drive a car or operate machinery and get up slowly from bed while taking this medication.
• Avoid abrupt withdrawal.
